Permit Application No. 2005-004

Activity for Which Permit Is Requested

Enter Antarctic Specially Protected Areas. The applicant proposes take photographs of named geographic features throughout the McMurdo Sound region. The photographs will illustrate a geographically arranged gazetteer or "field guide" to the features. The applicant proposes to enter the Barwick Valley, Victoria Land (ASPA #123) to fully document the Barwick Valley features which will benefit the scientific community in current and future work. Delineating data accompanying each photograph will include latitude, longitude, altitude, date, time, elevation, look direction, focal length and associated camera settings. The photographs and accompanying data will provide the potential for contemporary and future comparative studies of landscape change, thereby reducing need for access to the ASPA. The applicant proposes approximately 5-days work in the Barwick Valley and will fully comply with the designated management plan for the site. Furthermore, the applicant will visit Cape Crozier (ASPA #124) to film Wilson's Stone Igloo and The Knoll, avoiding the penguin and skua rookeries.

In addition, the applicant proposes to enter Discovery Hut (ASPA #157), Cape Evans Historic Site (ASPA #154), and Hut and Associated Artifacts, Backdoor Bay, Cape Royds (ASPA #156) for the purpose of reproducing historic photos of the area for use in the described gazetteer.

Location

ASPA #123—Barwick Valley, Victoria Land

ASPA #124—Cape Crozier, Ross Island ASPA #154—Cape Evans Historic Site

ASPA #156—Hut and associated artifacts, Backdoor Bay, Cape Royds, Ross Island

ASPA #157—Discovery Hut, Hut Point, Ross Island

Dates

August 22, 2004 to February 15, 2006.

Nadene G. Kennedy,

Permit Officer, Office of Polar Programs.

[FR Doc. 04–11702 Filed 5–24–04; 8:45 am]

BILLING CODE 7555–01–M

DEPARTMENT OF NATIONAL SCIENCE FOUNDATION

Proposal Review; Notice of Meetings

In accordance with the Federal Advisory Committee Act (Pub. L. 92-463, as amended), the National Science Foundation (NSF) announces its intent to hold proposal review meetings throughout the year. The purpose of these meetings is to provide advice and recommendations concerning proposals submitted to the NSF for financial support. The agenda for each of these meetings is to review and evaluate proposals as part of the selection process for awards. The review and evaluation may also include assessment of the progress of awarded proposals. The majority of these meetings will take place as NSF, 4201 Wilson, Blvd., Arlington, Virginia 22230.

These meetings will be closed to the public. The proposals being reviewed include information of a proprietary or confidential nature, including technical information; financial data, such as salaries; and personal information concerning individuals associated with the proposals. These matters are exempt under 5 U.S.C. 552b(c), (4) and (6) of the Government in the Sunshine Act. NSF will continue to review the agenda and merits of each meeting for overall compliance of the Federal Advisory Committee Act.

These closed proposal review meetings will not be announced on an individual basis in the Federal Register. NSF intends to publish a notice similar to this on a quarterly basis. For an advance listing of the closed proposed review meetings that include the names of the proposal review panel and the time, date, place, and any information on changes, corrections, or cancellations, please visit the NSF Website: http://www.nsf.gov/home/pubinfo/advisory.htm. This information may also be requested by telephone (703) 292—8182.

Dated: May 19, 2004.

Susanne Bolton,

Committee Management Officer. [FR Doc. 04–11700 Filed 5–24–04; 8:45 am] BILLING CODE 7555–01–M

NATIONAL SCIENCE FOUNDATION

Sunshine Act Meeting

Agency Holding Meeting: National Science Foundation, National Science Board and its Subdivisions.

Federal Register *Citation of Previous Announcement:* Volume 69, Number 84,

Federal Register, pages 23823–23824, April 30, 2004

Previously Announced Date and Time: Monday, May 3, 2004.

Additional Concurrent Session

Open

National Science Board, *ad hoc* Task Group on High Risk Research (11:00— 11:30 a.m.), Room 1295.

Place: The National Science Foundation, 4201 Wilson Boulevard, Arlington, VA 22230, www.nsf.gov/ nsb.

Contact for Information: National Science Board Office (703) 202–7000 Status: Open.

Changes in the Meeting: A half-hour open meeting was added to the agenda after the schedule was published in the **Federal Register**. Public announcement of this additional session was made on the National Science Board Web site ahead of the meeting. The following topic was discussed.

Discussion: Discussion of Workshop and White Paper.

Michael P. Crosby,

Executive Officer, NSB.
[FR Doc. 04–11939 Filed 5–21–04; 2:58 pm]
BILLING CODE 7555–01–M

NUCLEAR REGULATORY COMMISSION

[Docket No. 50-336 and 50-423 ASLBP No. 04-824-01-LR]

Dominion Nuclear Connecticut; Establishment of Atomic Safety and Licensing Board

Pursuant to delegation by the Commission dated December 29, 1972, published in the **Federal Register**, 37 FR 28,710 (1972), and the Commission's regulations, *see* 10 CFR 2.104, 2.300, 2.303, 2.309, 2.311, 2.318, and 2.321, notice is hereby given that an Atomic Safety and Licensing Board is being established to preside over the following proceeding:

Dominion Nuclear Connecticut (Millstone Nuclear Power Station, Units 2 and 3)

Pursuant to a March 8, 2004 notice of opportunity for hearing published in the **Federal Register** (69 FR 11,897 (Mar. 12, 2004)), and a May 4, 2004 Commission memorandum and order, CLI–04–12, 59 NRC_(May 4, 2004), a Licensing Board is being established to conduct a proceeding on the March 22, 2004 hearing petition of Connecticut Coalition Against Millstone (CCAM) regarding the January 22, 2004

Dominion Nuclear Connecticut applications for renewal of the Millstone Units 2 and 3 operating licenses.

The Board is comprised of the following administrative judges:
Dr. Paul B. Abramson, Chair, Atomic Safety and Licensing Board Panel,
U.S. Nuclear Regulatory Commission,
Washington, DC 20555–0001.

Ann Marshall Young, Atomic Safety and Licensing Board Panel, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001.

Dr. Richard F. Cole, Atomic Safety and Licensing Board Panel, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001.

All correspondence, documents, and other materials shall be filed with the administrative judges in accordance with 10 CFR 2.302.

Issued at Rockville, Maryland, this 19th day of May 2004.

G. Paul Bollwerk, III,

Chief Administrative Judge, Atomic Safety and Licensing Board Panel.

[FR Doc. 04–11755 Filed 5–24–04; 8:45 am] BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

[Docket No. 030-34781]

Notice of Availability of Environmental Assessment and Finding of No Significant Impact for License Amendment for Message Pharmaceuticals, Inc.'s Facility in Malvern, PA

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of Availability of Environmental Assessment and Finding of No Significant Impact.

FOR FURTHER INFORMATION CONTACT:

Sattar Lodhi, Nuclear Materials Safety Branch 2, Division of Nuclear Materials Safety, Region I, 475 Allendale Road, King of Prussia, Pennsylvania, 19406, telephone (610) 337–5364 fax (610) 337– 5269; or by e-mail: asl@nrc.gov.

SUPPLEMENTARY INFORMATION:

I. Introduction

The Nuclear Regulatory Commission (NRC) is considering the issuance of a license amendment to Message Pharmaceuticals, Inc.'s Materials License No. 37–30462–01, to authorize release of its facility in Malvern, Pennsylvania for unrestricted use. NRC has prepared an Environmental Assessment (EA) in support of this action in accordance with the

requirements of 10 CFR part 51. Based on the EA, the NRC has concluded that a Finding of No Significant Impact (FONSI) is appropriate. The amendment will be issued following the publication of this Notice.

II. EA Summary

The purpose of the proposed action is to authorize the release of the licensee's Malvern, Pennsylvania facility for unrestricted use. Message Pharmaceuticals, Inc., was authorized by NRC from July 29, 1998, to use radioactive materials for research and development purposes at the site. On January 5, 2004, Message Pharmaceuticals, Inc., requested that NRC release the facility for unrestricted use. Message Pharmaceuticals, Inc., has conducted surveys of the facility and determined that the facility meets the license termination criteria in Subpart E of 10 CFR part 20. The NRC staff has prepared an EA in support of the proposed license amendment.

III. Finding of No Significant Impact

The staff has prepared the EA (summarized above) in support of the proposed license amendment to terminate the license and release the facility for unrestricted use. The NRC staff has evaluated Message Pharmaceuticals, Inc.'s request and the results of the surveys and has concluded that the completed action complies with the criteria in Subpart E of 10 CFR part 20. The staff has found that the environmental impacts from the proposed action are bounded by the impacts evaluated by the "Generic Environmental Impact Statement in Support of Rulemaking on Radiological Criteria for License Termination of NRC-Licensed Facilities" (NUREG-1496). On the basis of the EA, the NRC has concluded that the environmental impacts from the proposed action are expected to be insignificant and has determined not to prepare an environmental impact statement for the proposed action.

IV. Further Information

The EA and the documents related to this proposed action, including the application for the license amendment and supporting documentation, are available for inspection at NRC's Public Electronic Reading Room at http://www.nrc.gov/reading-rm/adams.html (ADAMS Accession Nos. ML040250011 and ML041040862). These documents are also available for inspection and copying for a fee at the Region I Office, 475 Allendale Road, King of Prussia, Pennsylvania, 19406. Persons who do not have access to ADAMS, should

contact the NRC PDR Reference staff by telephone at 1–800–397–4209 or (301) 415–4737, of by e-mail to pdr@nrc.gov.

For the Nuclear Regulatory Commission. Dated at King of Prussia, Pennsylvania this 18th day of May, 2004.

John D. Kinneman,

Chief, Nuclear Materials Safety Branch 2, Division of Nuclear Materials Safety Region

[FR Doc. 04–11758 Filed 5–24–04; 8:45 am] BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

[Docket Nos. 050-00135 (Retired) and 030-01317]

Notice of Availability of Environmental Assessment and Finding of No Significant Impact for License Amendement for Department of the Army, Walter Reed Army Medical Center Washington, DC

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of Availability of Environmental Assessment and Finding of No Significant Impact.

FOR FURTHER INFORMATION CONTACT:

Laurie Peluso, Decommissioning Branch, Division of Nuclear Materials Safety, Region I, 475 Allendale Road, King of Prussia, Pennsylvania, 19406, telephone (610) 337–5323, fax (610) 337–5269; or by email: *LAP@nrc.gov*.

SUPPLEMENTARY INFORMATION:

I. Introduction

The Nuclear Regulatory Commission (NRC) is considering the issuance of a license amendment to Department of Army, Walter Reed Medical Center for Materials License No. 08-01738-02, to authorize release of Building 40 of the Washington, DC site for unrestricted use. NRC has prepared an Environmental Assessment (EA) in support of this action in accordance with the requirements of 10 CFR part 51. Based on the EA, the NRC has concluded that a Finding of No Significant Impact (FONSI) is appropriate. The amendment will be issued following the publication of this Notice.

II. EA Summary

The purpose of the proposed action is to authorize the release of the licensee's Building 40 of the Washington, DC facility for unrestricted use. WRAMC was authorized by the U.S. Atomic Energy Commission (AEC) from February 18, 1959 to use radioactive